Drug Trial Radar · NCT05694533
Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults
Last checked: Nov 19, 2026Latest source record: May 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Mar 16, 2023
Primary completion
Apr 6, 2023
Study completion May 1, 2023
Sponsor
- Lead sponsor
- Indivior Inc.Industry
- Sponsor type
- Industry
- Collaborators
- National Institute on Drug Abuse (NIDA)
- First posted
- Jan 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the potential for cytochrome P450 (CYP) 3A4 induction after dosing with INDV-2000 via use of midazolam as a probe.
Conditions
- Healthy
Interventions
INDV-2000Drug
Capsules administered orally twice a day
MidazolamDrug
Midazolam syrup administered orally on Days 1 and 15
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax) of Midazolam and 1-hydroxymidazolamTime frame: Day 1 and Day 15
- Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Midazolam and 1-hydroxymidazolamTime frame: Day 1 and Day 15
- Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam and 1-hydroxymidazolamTime frame: Day 1 and Day 15
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion
Tempe, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.